Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A four-component research blend of three short synthetic peptides and a 24-residue E-peptide fragment corresponding to a splice variant of the IGF-1 gene, characterized by sequence, molecular formula, and structural class.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Peptide blend
Molecular formula
C45H55N9O6
Molecular weight
817.97 g/mol
CAS number
158861-67-7
Sequence
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Molecular formula
C221H366N72O67S
Molecular weight
5135.89 g/mol
CAS number
218949-48-5
Molecular formula
C121H200N42O39
Molecular weight
2888.16 g/mol
Sequence
YQPPSTNKNTKSQRRKGSTFEEHK
Molecular formula
C38H49N9O5
Molecular weight
711.87 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
GHRP-2 and Ipamorelin are short synthetic peptides built largely from non-standard and D-configured residues. GHRP-2 is a hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) and Ipamorelin is a C-terminally amidated pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2); both carry a class of small peptides that engage a G-protein-coupled receptor, and their D-amino-acid content and C-terminal amidation confer protease resistance. LUV TES is a large synthetic peptide whose sequence is based on a 44-residue hypothalamic peptide; a hexenoyl modification at the N-terminus distinguishes it structurally from the native sequence and stabilizes the molecule. MGF is a 24-residue C-terminal E-peptide fragment whose sequence (YQPPSTNKNTKSQRRKGSTFEEHK) corresponds to a mechanical-stress-induced splice variant of the IGF-1 gene (IGF-1Ec); its primary structure is distinct from that of full-length IGF-1.
Lyophilized
GHRP-2, MGF, Ipamorelin: -20°C to -80°C. LUV TES: 2–8°C.
Avoid repeated freeze-thaw cycles for GHRP-2, MGF, and Ipamorelin. Protect LUV TES from light.
Reviews
Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. (2020). JCSM Rapid Communications
Sinha DK, Balasubramanian A, Rivera-Vega MR, et al. (2020). Translational Andrology and Urology
Mosińska P, Zatorski H, Storr M. (2017). Journal of Neuroendocrinology
Reviews
Goldspink G. (2010). Endocrinology
Primary research
Beck IT, Sweeny WB, McCarter MD, et al. (2014). International Journal of Colorectal Disease
Mamputu JC, Falutz J, Potvin D, et al. (2012). Clinical Infectious Diseases
Falutz J, Mamputu JC, Potvin D, et al. (2010). Journal of Clinical Endocrinology & Metabolism
Falutz J, Allas S, Blot K, et al. (2007). New England Journal of Medicine
Pihoker C, Pescovitz OH, Rogol AD, et al. (1995). Journal of Clinical Endocrinology & Metabolism
Tauber M, Pihoker C, Rogol AD, et al. (1993). Journal of Clinical Endocrinology & Metabolism
Zhang B, Liu Z, Li X, et al. (2023). International Journal of Molecular Medicine
Venkova K, Mann W, Nelson R, et al. (2009). Journal of Pharmacology and Experimental Therapeutics
Dluzniewska J, Sarnowska A, Lee J, et al. (2005). FASEB Journal
Laferrère B, Bressler P, David D, et al. (2002). Journal of Clinical Endocrinology & Metabolism
Yang SY, Goldspink G. (2002). FEBS Letters
Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Lancet HIV
Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. (2011). Mechanisms of Ageing and Development
Raun K, Hansen BS, Johansen NL, et al. (1998). European Journal of Endocrinology
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| GHRP-2 + LUV TES + MGF + IpamorelinThis page | Peptide blend | — | — |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods